CD19 and diffuse large B-cell lymphoma: Thirteen patients, 6 of whom were included in another paper to compare the effect of different co-stimulatory domains on the clinical outcomes of CD19 CAR-T cells [8], with diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL) or marginal zone lymphoma (MZL), were enrolled in this clinical trial.